This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

New Neurosurgical Partnership Advances Patient Care At Cancer Treatment Centers Of America® At Midwestern Regional Medical Center

ZION, Ill., April 30, 2012 /PRNewswire/ -- In a new partnership with Chicago area-based American Center for Spine and Neurosurgery (ACSN), Cancer Treatment Centers of America ® (CTCA) at Midwestern Regional Medical Center (Midwestern) expands its services to include neurosurgery.  CTCA patients with cancer of the central nervous system will be provided with the comfort of undergoing surgery in-house with the state-of-the-art technology and space now available in the new surgical center at CTCA at Midwestern.  Together, the ACSN and CTCA at Midwestern are committed to improving quality of life, introducing new technology and exploring new avenues of treatment. 

To view the multimedia assets associated with this release, please click http://www.prnewswire.com/news-releases/new-neurosurgical-partnership-advances-patient-care-at-cancer-treatment-centers-of-america-at-midwestern-regional-medical-center-149530145.html

(Logo: http://photos.prnewswire.com/prnh/20090612/CTCALOGO)

"Our promise has always been to rally our medical expertise around the patient," said Anne Meisner, president and CEO of CTCA at Midwestern. "That includes providing comprehensive medical treatments like chemotherapy, radiation and surgery under one roof.  As we strive to continually lead the health care industry in providing advanced options for cancer treatment, the addition of neurosurgery to our surgical services is a key investment into the care of our patients." 

"Neurosurgery is a powerful tool in the fight against cancer," said Meisner. "It is a highly specialized field of surgery that can offer hope to many of our patients.  I am proud to add neurosurgery to the arsenal of treatment options available to CTCA at Midwestern patients as they battle this disease."

In this new agreement, Juan C. Alzate, MD, of the ACSN will perform neurosurgical procedures such as tumor removal, spinal tumor resection and stereotaxic brain biopsy at Midwestern.  Previously, patients at Midwestern undergoing neurosurgery traveled for consult and surgery. 

According to Charles Komen Brown, MD, PhD and medical director of surgery and surgical oncology at CTCA at Midwestern, "The American Center for Spine and Neurosurgery is a leader in spine, brain and nerve care, with a focus on helping patients minimize pain and symptoms to facilitate a quick return to the activities they enjoy.  We are very excited to welcome Dr. Juan Alzate to our team." 

Dr. Alzate is a member of the Congress of Neurological Surgeons, the American Association of Neurological Surgeons, and the North American Spine Society.  Dr. Alzate is fluent in English and Spanish and has published many articles in peer-reviewed journals, authored many book chapters and has spoken at numerous conferences both in the U.S. and Colombia.

"I am very excited to embark on a new relationship with CTCA at Midwestern patients," said Alzate. "The surgical staff at CTCA at Midwestern is highly trained and responsive.  As a leader on this team, I am committed to working with patients to develop an individualized approach that meets their needs and helps them return quickly to family, work and the things that they enjoy."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,135.17 +38.27 0.21%
S&P 500 2,100.25 +1.72 0.08%
NASDAQ 4,979.1220 +11.9810 0.24%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs